MedPath

Tagged News

Alectinib Plus Bevacizumab Shows Promising Results in First-Line Treatment of ALK-Positive NSCLC

Precision MedicineOncologyTargeted Therapy
  • The ALEK-B phase 2 trial demonstrated that combining alectinib with bevacizumab significantly improved progression-free survival in ALK-positive NSCLC patients, with 97% remaining progression-free at 12 months and 64% at 36 months.
  • The combination therapy showed remarkable efficacy in preventing CNS progression, with a 36-month intracranial progression-free survival rate of 87.8% and only 8.8% cumulative incidence of new brain metastases.
  • Despite higher rates of adverse events compared to alectinib monotherapy, particularly proteinuria (70.7%) leading to bevacizumab discontinuation in 43.9% of patients, the treatment maintained quality of life improvements throughout the study period.

Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)

NCT05200481Active, Not RecruitingPhase 2
Intergroupe Francophone de Cancerologie Thoracique
Posted 5/18/2022

Alectinib in Combination With Bevacizumab in ALK Positive NSCLC

NCT03779191CompletedPhase 2
Instituto Nacional de Cancerologia de Mexico
Posted 4/8/2020

Rakovina Therapeutics Secures $4M Strategic Financing to Advance AI-Powered Cancer Drug Discovery Platform

AIDrug DiscoveryOncology
  • Rakovina Therapeutics announced a strategic $4 million financing round anchored by $3 million from strategic investors to support its AI-powered oncology drug discovery platform.
  • The company will implement a 10-for-1 share consolidation to enhance its capital structure and position for accelerated growth in U.S. capital markets.
  • The financing will support Rakovina's proprietary DNA Damage Response platform targeting treatment-resistant cancers with impaired DNA repair pathways.
  • The company aims to advance its pipeline of DNA-damage response inhibitors toward human clinical trials through pharmaceutical partnerships.

Biodesix Presents New Data Showing Nodify Lung® Tests Improve Pulmonary Nodule Management

Real World EvidenceOncology
  • New study of over 350,000 patients reveals significant gaps in lung nodule management, with approximately two-thirds receiving no clinical work-up after nodule discovery.
  • Research presented at ISPOR 2025 shows concerning rates of mismanagement, with 60% of biopsies performed on benign nodules and 35% of malignant nodules receiving only follow-up CT scans.
  • Real-world data from a safety-net hospital demonstrates how Biodesix's Nodify Lung® testing can guide clinical decisions through actionable results in pulmonary nodule risk stratification.

Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects

NCT03289780Active, Not Recruiting
Biodesix, Inc.
Posted 4/4/2016

Avacta's pre|CISION Technology Makes Toxic Chemotherapy Safer and More Effective

Targeted TherapyOncology
  • Avacta has developed a novel "masked" chemotherapy approach called pre|CISION that dramatically improves safety profiles of toxic cancer drugs while maintaining therapeutic efficacy.
  • The technology works by rendering chemotherapy inactive in normal tissues and only activating the drug when it reaches the tumor microenvironment, significantly reducing systemic toxicity.
  • Clinical applications of pre|CISION technology could potentially transform cancer treatment by allowing higher dosing of potent chemotherapeutics and expanding treatment options for patients who cannot tolerate conventional chemotherapy.

China Approves Xuanyuening (Bireociclib): First Dual-Indication CDK Inhibitor for Advanced Breast Cancer

Drug ApprovalTargeted TherapyOncology
  • China's NMPA has approved Xuanzhu Biopharm's Bireociclib (Xuanyuening®), a novel multi-target CDK inhibitor for HR+/HER2- advanced breast cancer with dual indications.
  • The drug can be used in combination with fulvestrant after endocrine therapy failure and is the only CDK4/6 inhibitor approved in China as monotherapy for heavily pretreated patients.
  • Clinical trials showed impressive efficacy with median PFS of 17.5 months in combination therapy and 11 months as monotherapy, addressing specific needs of Chinese breast cancer patients.

A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer

NCT05077449Active, Not RecruitingPhase 3
Xuanzhu Biopharmaceutical Co., Ltd.
Posted 11/16/2021

A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors

NCT04539496Unknown StatusPhase 1
Sihuan Pharmaceutical Holdings Group Ltd.
Posted 5/22/2018

Innate Pharma's Novel NK Cell Engager IPH6501 to Be Presented at EHA 2025 Congress

Oncology
  • Innate Pharma's IPH6501, a tetraspecific NK cell engager targeting CD20 B cells for Non-Hodgkin Lymphoma, will be featured at the European Hematology Association Congress in June 2025.
  • The ANKET® platform technology represents a new class of cancer immunotherapies that co-engage multiple receptors on NK cells while targeting tumor antigens, potentially offering superior efficacy to existing antibody treatments.
  • Preclinical data has shown IPH6501 demonstrates better anti-tumor efficacy than approved benchmark antibodies, with the compound currently being evaluated in a Phase 1/2 trial for relapsed/refractory CD20-expressing B-cell lymphomas.

A Phase 1/2, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of IPH6501 in Patients with Relapsed and/or Refractory CD20-expressing Non-Hodgkin Lymphoma

2023-506976-28-00RecruitingPhase 1/2
Innate Pharma

Camber Pharmaceuticals Launches Temozolomide Capsules for Brain Cancer Treatment

Oncology
• Camber Pharmaceuticals has announced the launch of Temozolomide Capsules, USP, an alkylating drug used in the treatment of glioblastoma and anaplastic astrocytoma in adults.
• The medication will be available in five different strengths (5mg, 20mg, 100mg, 140mg, 180mg, and 250mg) and in various count options to support different treatment regimens.
• Temozolomide is primarily used as a concurrent treatment with radiotherapy for newly diagnosed glioblastoma patients, followed by maintenance therapy, addressing critical needs in brain cancer treatment.

Hengrui Pharmaceuticals Aims to Raise $1.27 Billion in Hong Kong IPO

Oncology
  • Chinese pharmaceutical giant Jiangsu Hengrui plans to raise up to $1.27 billion in its Hong Kong IPO, making it one of the city's largest offerings this year.
  • The Shanghai-listed company, which focuses on oncology and metabolic diseases, has secured GIC, Invesco, and Hillhouse as cornerstone investors ahead of its expected May 23 trading debut.
  • Hengrui's offering comes amid a surge in Hong Kong's IPO market, with funds raised from new listings nearly quadrupling in the first quarter compared to last year.

GenVivo Reports Promising Phase 1 Data for GEN2 and Preclinical Results for GEN-1013 Cancer Immunotherapies at ASGCT 2025

Oncology
  • GenVivo's lead candidate GEN2, a non-replicating mRNA vector therapy, demonstrates favorable safety profile with minimal toxicity and encouraging pharmacodynamic activity in Phase 1 trials for solid tumors.
  • GEN-1013, the company's preclinical IL-12 encoding therapy, showed remarkable efficacy in murine cancer models with 89% of treated animals reaching study endpoints compared to just 11% in control groups.
  • Both therapies leverage GenVivo's innovative vector platform that activates patients' immune systems against their own tumor antigens, with GEN-1013 advancing toward IND filing by mid-2026.

Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors

NCT06391918RecruitingPhase 1
GenVivo, Inc.
Posted 3/4/2024

GEN2 Directed Cancer Immunotherapy Trial

NCT04313868CompletedPhase 1
GenVivo, Inc.
Posted 6/13/2014

Colorectal Cancer Leads in Real-World Data Volume, But Oncology Trials Need Modernization

Real World EvidenceAIPrecision MedicineOncology
• Phesi's analysis of 167 million patient records reveals colorectal cancer has the largest volume of real-world data with nearly six million records, outpacing breast, lung, liver, and prostate cancers.
• Despite the wealth of available data, oncology clinical trials continue to suffer from inefficiencies, with trial design and execution failing to keep pace with advances in biomarker science and patient profiling.
• Experts urge a shift toward "precision oncology" using AI and clinical data science to optimize patient profiles, programs, protocols, and operations plans to accelerate drug development.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.